30 August 2023

## Diaceutics PLC ("Diaceutics" or "the Company")

## PDMR Shareholding/Share Incentive Plan

Diaceutics PLC, (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, has been notified that on 29 August 2023, Global Shares Trustees (UK) Limited andZedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares ("Shares") on behalf of Susanne Munksted, Jordan Clark, Julie Browne and Nick Roberts (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employeesThese purchases will be made each month until further notice.

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.

## Enquiries:

Diaceutics PLC Nick Roberts, Chief Financial Officer

Stifel Nicolaus Europe Limited (Nomad & Broker) Ben Maddison Nick Harland Kate Hanshaw

Alma PR Caroline Forde Matthew Young Kinvara Verdon

About Diaceutics

Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com

Tel: +44 (0)20 7710 7600

Tel: +44(0)20 3405 0205 diaceutics@almapr.co.uk

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

1	Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Susanne Munksted	
2	Reason for notification		
a.	Position/Status	Chief Precision Medicine Officer	
b.	Initial notification/ Amendment	Initial	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a.	Name	Diaceutics PLC	
		213800VEWQBB39ZB8J81	

	transaction; (iii) each date;	; and (	iv) each place where t	ransactions have been cond	ucted	
a.	Description of the financial instrument, type of instrument	Ordinary shares of £0.002 each				
	Identification Code	ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")				
с.	Price(s) and volume(s)		Share purchase:			
			Price(s)	Volume(s)		
			1.075 p	136		
			Conditional share award:			
			Price(s)	Volume(s)		
			Nil	136		
e.	Date of the transaction	Share purchase and Conditional share award: 29 August 2023				
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market				

Notifi	cation of a Transaction pursu	nt to Article 19(1) of Regulation (EU) No. 596/2014				
1	Details of the person discharging managerial responsibilities/person closely associated					
a.	Name	Jordan Clark				
2	Reason for notification					
a.	Position/Status	Chief Commercial Officer				
b.	Initial notification/ Amendment	Initial				
3	Details of the issuer, emis monitor	ssion allowance market participant, auction platform, auctioneer or auction				
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4		(s): section to be repeated for (i) each type of instrument; (ii) each type of ;; and (iv) each place where transactions have been conducted				
a.	Description of the financial instrument, type of instrument	Ordinary shares of £0.002 each				
	Identification Code	ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")				
с.	Price(s) and volume(s)	Share purchase:				
		Price(s) Volume(s)				
		1.075 p 139				
I	1					

			Matched share award:		
			Price(s)	Volume(s)	
			1.075 p	139	
e.	Date of the transaction	Share purchase and Matched Share award: 29 August 2023			
f.	Place of the transaction	Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange			

Notific	cation of a Transaction pursu	ant to Article 19(1) of I	Regulation (EU) No. 596/20	114	
1	Details of the person disch	arging managerial resp	onsibilities/person closely	associated	
а.	Name	Julie Browne			
2	Reason for notification	1			
a.	Position/Status	Chief Operations Offi	cer		
b.	Initial notification/	Initial			
	Amendment				
3	Details of the issuer, emis monitor	sion allowance market	participant, auction platfor	m, auctioneer or auction	
a.	Name	Diaceutics PLC			
b.	LEI	213800VEWQBB39ZB	8J81		
4		s): section to be repeated for (i) each type of instrument; (ii) each type of ; and (iv) each place where transactions have been conducted			
a.	Description of the financial instrument, type of instrument	Ordinary shares of £0.002 each			
	Identification Code	ISIN: GB00BJQTGV64			
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")			
с.	Price(s) and volume(s)	Share purchase	::		
		Price(s)	Volume(s)		
		1.075 p	139		
		Matched share award:			
		Price(s)	Volume(s)		
		1.075 p	139		
e.	Date of the transaction	Share purchase and N	Matched Share award: 29 A	lugust 2023	
f.	Place of the transaction	Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange			

NOTI	ication of a Transaction pur	suant to Article 19(1) of	Regulation (EO) No. 596/.	2014		
1	Details of the person discharging managerial responsibilities/person closely associated					
a.	Name	Nick Roberts				
2	Reason for notification					
а.	Position/Status	Chief Finance Officer	Chief Finance Officer			
b.	Initial notification/	Initial				
3		ission allowance market	ion allowance market participant, auction platform, auctioneer or auction			
	monitor			_		
a.	Name	Diaceutics PLC	Diaceutics PLC			
b.	LEI	213800VEWQBB39ZE	38J81			
4			ted for (i) each type of ins ere transactions have be	strument; (ii) each type of en conducted		
a.	Description of the financial instrument, type of instrument	Ordinary shares of £0.002 each				
	Identification Code	ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")				
c.	Price(s) and volume(s)	Share purchase:				
		Price(s)	Volume(s)			
		1.075 p	139			
		Matched shar	Matched share award:			
		Price(s)	Volume(s)			
		1.075 p	139			
е.	Date of the transaction	Share purchase and	Matched Share award: 29	August 2023		
	Place of the transaction	Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <u>ms@lseg.com</u> or visit <u>www.ms.com</u>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END